(S (NP (NN Drug) (NN repurposing)) (VP (VBZ is) (NP (DT an) (JJ effective) (NN strategy) (S (VP (TO to) (VP (VB identify) (NP (NP (JJ new) (NNS uses)) (PP (IN for) (NP (VBG existing) (NNS drugs)))) (, ,) (S (VP (VBG providing) (NP (NP (DT the) (JJS quickest) (JJ possible) (NN transition)) (PP (IN from) (NP (NN bench)))) (PP (IN to) (NP (NN bedside)))))))))) (. .))
(S (NP (NP (VBG Existing) (NNS methods)) (PP (IN for) (NP (NP (NN drug)) (VP (VBG repurposing) (SBAR (IN that) (S (ADVP (RB mainly)) (VP (VB focus) (PP (IN on) (NP (JJ pre-clinical) (NN information)))))))))) (VP (MD may) (VP (VB exist) (NP (JJ translational) (NNS issues)) (SBAR (WHADVP (WRB when)) (S (VP (VBN applied) (PP (IN to) (NP (JJ human) (NNS beings)))))))) (. .))
(S (NP (NP (NP (JJ Real) (NN world) (NNS data)) (-LRB- -LRB-) (NP (NN RWD)) (-RRB- -RRB-)) (, ,) (PP (JJ such) (IN as) (NP (NP (JJ electronic) (NN health) (NNS records)) (CC and) (NP (NN insurance) (NNS claims)))) (, ,)) (VP (VBP provide) (NP (NN information)) (PP (IN on) (NP (NP (JJ large) (NNS cohorts)) (PP (IN of) (NP (NP (NNS users)) (PP (IN for) (NP (JJ many) (NNS drugs)))))))) (. .))
(S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP present) (NP (NP (DT an) (ADJP (ADJP (JJ efficient)) (CC and) (ADJP (RB easily) (HYPH -) (VBN customized))) (NN framework)) (PP (IN for) (S (VP (VBG generating) (CC and) (VBG testing) (NP (NP (JJ multiple) (NNS candidates)) (PP (IN for) (NP (NP (NN drug)) (VP (VBG repurposing) (S (VP (VBG using) (NP (NP (DT a) (JJ retrospective) (NN analysis)) (PP (IN of) (NP (NNS RWDs))))))))))))))) (. .))
(S (NP (NP (ADVP (NP (NNP Building)) (PP (RB upon))) (NML (NML (ADJP (ADJP (RB well) (HYPH -) (VBN established)) (JJ causal)) (NN inference)) (CC and) (NML (JJ deep) (NN learning))) (NNS methods)) (, ,) (NP (PRP$ our) (NN framework))) (VP (VBZ emulates) (S (NP (NP (JJ randomized) (JJ clinical) (NNS trials)) (PP (IN for) (NP (NNS drugs)))) (ADJP (JJ present) (PP (IN in) (NP (DT a) (NML (JJ large) (HYPH -) (NN scale)) (NML (JJ medical) (NNS claims)) (NN database)))))) (. .))
(S (NP (PRP We)) (VP (VBP demonstrate) (NP (PRP$ our) (NN framework)) (PP (IN in) (NP (NP (DT a) (NN case) (NN study)) (PP (IN of) (NP (JJ coronary) (NN artery) (NN disease) (PRN (-LRB- -LRB-) (NP (NN CAD)) (-RRB- -RRB-)))))) (PP (IN by) (S (VP (VBG evaluating) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (CD 55) (VBG repurposing) (NN drug) (NNS candidates)) (PP (IN on) (NP (JJ various) (NN disease) (NNS outcomes)))))))))) (. .))
(S (NP (PRP We)) (VP (VBP achieve) (NP (NP (CD 6) (NN drug) (NNS candidates)) (SBAR (WHNP (WDT that)) (S (ADVP (RB significantly)) (VP (VP (VBP improve) (NP (DT the) (NN CAD) (NNS outcomes))) (CONJP (CC but) (RB not)) (VP (VB have) (VP (VBN been) (VP (VBN indicated) (PP (IN for) (S (VP (VBG treating) (NP (NNP CAD)))))))))))) (, ,) (S (VP (VBG paving) (NP (NP (DT the) (NN way)) (PP (IN for) (NP (NN drug) (NN repurposing))))))) (. .))
